dalteparin has been researched along with Cancer of Esophagus in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current treatment approaches for esophageal cancer are associated with poor survival, and there are ongoing efforts to find new and more effective therapeutic strategies." | 2.90 | A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer. ( Akhavan Rezayat, K; Avan, A; Fanipakdel, A; Ferns, GA; Gholami, A; Hosseini, S; Javadinia, SA; Joudi Mashhad, M; Taghizadeh Kermani, A; Zardadi, M, 2019) |
| "This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery." | 2.90 | Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019) |
| " In addition, the incidence of all enoxaparin treatment- and operation-related adverse events was investigated." | 2.87 | Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety. ( Baba, H; Baba, Y; Hiyoshi, Y; Imamura, Y; Ishimoto, T; Iwatsuki, M; Miyamoto, Y; Watanabe, M; Yoshida, N, 2018) |
| "Patients with oesophageal cancer undergoing neoadjuvant chemoradiotherapy and surgery are at substantial risk of thromboembolic and bleeding events throughout all stages of treatment." | 1.56 | Thromboembolic and bleeding complications in patients with oesophageal cancer. ( Büller, HR; Hovenkamp, A; Hulshof, MCCM; Kamphuisen, PW; Middeldorp, S; Mulder, FI; van Berge Henegouwen, MI; van Es, N; van Laarhoven, HWM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mulder, FI | 1 |
| Hovenkamp, A | 1 |
| van Laarhoven, HWM | 1 |
| Büller, HR | 1 |
| Kamphuisen, PW | 1 |
| Hulshof, MCCM | 1 |
| van Berge Henegouwen, MI | 1 |
| Middeldorp, S | 1 |
| van Es, N | 1 |
| Yoshida, N | 1 |
| Baba, Y | 1 |
| Miyamoto, Y | 1 |
| Iwatsuki, M | 1 |
| Hiyoshi, Y | 1 |
| Ishimoto, T | 1 |
| Imamura, Y | 1 |
| Watanabe, M | 1 |
| Baba, H | 1 |
| Taghizadeh Kermani, A | 1 |
| Hosseini, S | 1 |
| Fanipakdel, A | 1 |
| Joudi Mashhad, M | 1 |
| Akhavan Rezayat, K | 1 |
| Zardadi, M | 1 |
| Gholami, A | 1 |
| Javadinia, SA | 1 |
| Ferns, GA | 1 |
| Avan, A | 1 |
| Tanaka, Y | 1 |
| Yamada, A | 1 |
| Hirata, S | 1 |
| Tanaka, H | 1 |
| Sakuratani, T | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Shimokawa, T | 1 |
| Yoshida, K | 1 |
| Byrne, M | 2 |
| Reynolds, JV | 1 |
| O'Donnell, JS | 1 |
| Keogan, M | 1 |
| White, B | 1 |
| Murphy, S | 1 |
| Maher, SG | 1 |
| Pidgeon, GP | 1 |
| Rollins, KE | 1 |
| Peters, CJ | 1 |
| Safranek, PM | 1 |
| Ford, H | 1 |
| Baglin, TP | 1 |
| Hardwick, RH | 1 |
3 trials available for dalteparin and Cancer of Esophagus
| Article | Year |
|---|---|
Prophylaxis of Postoperative Venous Thromboembolism Using Enoxaparin After Esophagectomy: A Prospective Observational Study of Effectiveness and Safety.
Topics: Aged; Anticoagulants; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Hu | 2018 |
A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Enoxaparin; Esophageal Ne | 2019 |
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We | 2019 |
3 other studies available for dalteparin and Cancer of Esophagus
| Article | Year |
|---|---|
Thromboembolic and bleeding complications in patients with oesophageal cancer.
Topics: Adenocarcinoma; Aged; Anticoagulants; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; E | 2020 |
Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.
Topics: Adenocarcinoma; Adult; Aged; Anticoagulants; Biomarkers; Carcinoma, Squamous Cell; Combined Modality | 2010 |
Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |